Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBLI Cleveland BioLabs	$0.00	$3.19	$1.62 ▼ $10.97	$9K	0.7	271,922 shs	55 shs
HPPI HedgePath Pharmaceuticals	$0.07	$0.07	$0.04 ▼ $0.32	$25.38M	-1.16	19,283 shs	N/A
TENX Tenax Therapeutics	$3.63 -1.4%	$4.02	$3.48 ▼ $61.20	$7.11M	2.25	294,890 shs	13,788 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBLI Cleveland BioLabs	0.00%	0.00%	0.00%	0.00%	-97.14%
HPPI HedgePath Pharmaceuticals	-6.80%	-11.61%	-2.14%	-31.50%	+197.83%
TENX Tenax Therapeutics	+2.51%	-4.17%	-3.66%	-62.30%	-87.15%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	2.445 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	3.00	Buy	$480.00	13,123.14% Upside

Current Analyst Ratings

Latest CBLI, HPPI, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/20/2024	TENX Tenax Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBLI Cleveland BioLabs	$260K	0.04	N/A	N/A	$0.87 per share	0.00
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$27.15 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBLI Cleveland BioLabs	-$2.40M	N/A	∞	N/A	N/A	-32.84%	-31.29%	N/A
HPPI HedgePath Pharmaceuticals	-$4.55M	N/A	∞	N/A	N/A	N/A	-246.03%	N/A
TENX Tenax Therapeutics	-$7.71M	N/A	N/A	N/A	N/A	-65.79%	-58.31%	5/20/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBLI Cleveland BioLabs	N/A	N/A	N/A	N/A	N/A
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBLI Cleveland BioLabs	N/A	45.93	45.93
HPPI HedgePath Pharmaceuticals	N/A	6.76	6.76
TENX Tenax Therapeutics	N/A	3.26	3.26

Ownership

Institutional Ownership

Company	Institutional Ownership
CBLI Cleveland BioLabs	5.09%
HPPI HedgePath Pharmaceuticals	N/A
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
CBLI Cleveland BioLabs	1.03%
HPPI HedgePath Pharmaceuticals	4.80%
TENX Tenax Therapeutics	1.85%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CBLI Cleveland BioLabs	4	15.48 million	N/A	Not Optionable
HPPI HedgePath Pharmaceuticals	2	370.45 million	N/A	Not Optionable
TENX Tenax Therapeutics	7	1.96 million	1.92 million	Not Optionable

CBLI, HPPI, and TENX Headlines

Source	Headline
	Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Rises By 33.5% americanbankingnews.com - April 15 at 5:16 AM
	TENX: 2023 Financial Results finance.yahoo.com - April 9 at 12:56 PM
	Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” globenewswire.com - April 9 at 8:30 AM
	Tenax Therapeutics: Q4 Earnings Insights benzinga.com - March 28 at 10:25 PM
	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 msn.com - March 28 at 10:25 PM
	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results globenewswire.com - March 28 at 8:30 AM
	Former public company CEO now leads RTP firm bizjournals.com - March 20 at 8:28 PM
	Tenax Therapeutics to Present at the 36th Annual Roth Conference globenewswire.com - March 12 at 8:30 AM
	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 globenewswire.com - February 29 at 9:00 AM
	Tenax acquires global rights to oral, subcutaneous levosimendan pulmonaryhypertensionnews.com - February 21 at 5:58 PM
	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan finance.yahoo.com - February 20 at 9:56 AM
	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan globenewswire.com - February 20 at 8:30 AM
	TENX: First Patient Enrolled finance.yahoo.com - February 12 at 3:34 PM
	Chapel Hill pharma pushing PHT treatment opens $9M stock offering bizjournals.com - February 9 at 5:08 PM
	Why Tenax Therapeutics (TENX) Stock Is Getting Obliterated msn.com - February 8 at 4:05 PM
	Tenax Therapeutics Shares Plummet Premarket After Stock Offering marketwatch.com - February 8 at 11:05 AM
	Tenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63% markets.businessinsider.com - February 8 at 11:05 AM
	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering finance.yahoo.com - February 8 at 11:05 AM
	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? investorplace.com - February 8 at 10:03 AM
	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) finance.yahoo.com - February 8 at 12:17 AM
	Tenax Therapeutics Granted Patent for Heart Treatment Drugs msn.com - February 7 at 9:17 AM
	Tenax Shares Surge After Acceptance of Patent Application marketwatch.com - February 6 at 2:06 PM
	Tenax surges after patent win for heart failure therapy msn.com - February 6 at 2:06 PM
	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) finance.yahoo.com - February 6 at 9:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cleveland BioLabs

NASDAQ:CBLI

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

HedgePath Pharmaceuticals

OTCMKTS:HPPI

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Tenax Therapeutics

NASDAQ:TENX

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial